Clinical Trial Update: Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating adalimumab in mucopolysaccharidosis types I, II, and VI has completed phases 1 and 2 with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type
• Mucopolysaccharidosis Type Ii
• Mucopolysaccharidosis Type Vi

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Conditions: Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-09-15